logo-loader

Recce Pharmaceuticals tackling antibiotic-resistant ‘superbugs’ with synthetic anti-infectives

Last updated: 01:42 28 Mar 2024 GMT, First published: 03:34 07 Oct 2023 BST

Snapshot

  • Recce Pharmaceuticals gaining financial leverage and progressing clinical trials, says Edison Investment Research
  • The smart money in medicine: the silent pandemic
  • Recce Pharmaceuticals’ valuation lifted by Edison Investment Research following progress on RECCE 327
  • Recce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsis
Recce Pharmaceuticals Ltd

About the company

Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.

How it is doing

28 Mar 2024

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF), an innovator in broad-spectrum synthetic anti-infective drugs, has recently announced a considerable financial boost through an A$11.18 million research and development (R&D) advance credit from Endpoints Capital.

The financial infusion is set to extend Recce’s operational reach, allowing for the continued advancement of its R327 intravenous (IV) formulation.

“We believe this non-dilutive source of funding should extend Recce’s operating runway into FY25,” Edison Investment Research says in a recent report on the company.

The advance is earmarked for the anticipated R&D tax credit rebates for fiscal years 2023 through 2025, enhancing Recce's financial sustainability without diluting shareholder value.

21 Mar 2024

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has successfully registered its RECCE® trademark in Canada and is ready to take on that market with the added boost of R&D tax incentive rebates from the Canadian Revenue Agency.

The Canadian Intellectual Property Office awarded Recce with International Trademark Registration No. 1289603, corresponding to Canada Trademark No. 1225479, which specifically covers a range of antibiotic and pharmaceutical preparations.

15 Mar 2024

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has successfully completed dosing of its latest cohort in its Phase 1/2 UTI/urosepsis clinical trial, evaluating RECCE® 327 (R327) at fast infusion rates. 

Insight: The smart money in medicine: the silent pandemic

01 Mar 2023

Following years of COVID-19 and countless films and TV series about plagues and killer fungi, it’s fair to say that the world is now well attuned to the threat of a superbug apocalypse.

Disruptive pandemic aside, it has been a long time since humans reckoned with something as horrific as the Black Plague, which had mortality in the order of 30-50% – compared to COVID, which at its peak had a mortality rate of up to 3% – and condemned an estimated 75-200 million in Europe to a gruesome death.

What the brokers say

12 Jul 2023

Edison Investment Research has revised its valuation for Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) to A$535.6 million (or A$3.00 per share), up from A$497.4 million previously, following an eventful period for the company.

Recce secured ethics approval in April 2023 to start Phase I/II clinical trials in healthy volunteers for the intravenous (IV) formulation of its lead broad-spectrum synthetic polymer anti-infective compound, RECCE 327 (R327), using a more rapid infusion rate.

A Phase II efficacy study in patients with uncomplicated or recurrent urinary tract infections (UTIs) is expected to start in H2 CY23.

What management says

18 Mar 2024

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive to talk through significant progress in the journey of RECCE® 327 (R327) for treating urinary tract infections (UTI) and urosepsis. The company has completed dosing in its Phase 1/2 clinical trial, which focused on evaluating R327's safety and pharmacokinetics at fast infusion rates.

Following the completion of this phase of the trial, an independent safety committee will assess the data. This analysis is crucial for advancing to the next phase of research.

Recruitment has already started for the subsequent cohort, aiming to further investigate R327's effects and prepare for an efficacy trial. The ongoing studies are stepping stones towards potentially establishing R327 as a frontline treatment for UTI and urosepsis. Recce is now not far from transitioning into an efficacy trial.

Recce Pharma says commercial potential of its anti-infectives is gaining...

Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive soon after announcing the company has raised a total of around $11 million across its recent placement, entitlement offer and shortfall as it develops a new class of synthetic anti-infectives designed to...

on 11/10/23